Favipiravir Drug
- All
- News
- Videos
-
Ivermectin, HCQ Dropped From One Covid Treatment List, Kept On Another
The Union health ministry has issued revised guidelines for management of Covid-infected patients, dropping many sought-after drugs like ivermectin, hydroxychloroquine and anti-viral Favipiravir from Covid treatment.
-
19 States Mapped With Remdesivir Manufacturers For Faster Supply
The centre has mapped manufacturers of the anti-viral drug remdesivir with 19 states that have high Covid case burden. This will ensure smooth and fast delivery of the medicine, the centre said in a statement.
-
Lupin Launches COVID-19 Drug Favipiravir In India At Rs 49 Per Tablet
Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name "Covihalt" for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.
-
Lupin Launches Its Version Of Favipiravir Drug To Treat COVID-19
Lupin's Covihalt will be available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs 49 per tablet
-
Zenara Pharma Receives Nod To Sell Covid-19 Drug Favipiravir
Zenara Pharma: The Hyderabad-based company has received an approval to sell Favipiravir tablets for treating patients with mild to moderate symptoms of Covid-19.
-
Sun Pharma Company Launches COVID-19 Drug Favipiravir In India
Sun Pharmaceutical Industries has said it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.
-
Hetero Labs Wins Approval To Sell COVID-19 Drug Favipiravir
The drug, priced at Rs 59 per tablet, is approved to treat mild to moderate COVID-19
-
Cipla Gets Regulatory Nod To Sell COVID-19 Drug
Cipla said it would launch favipiravir as "Ciplenza" in the first week of August, priced at Rs 68 (91 cents) per 200 mg tablet.
-
Cipla Set To Launch Favipiravir Drug For Treatment Of COVID Patients
Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for the treatment of COVID-19 patients, according to an official statement on Thursday.
-
Glenmark Defends Price Of Its COVID-19 Drug Favipiravir Version
Glenmark denied making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate COVID-19 patients.
-
Central Drug Agency Seeks Clarification From Glenmark On Its COVID-19 Drug
The Drugs Controller General of India (DCGI) has asked for a clarification from Glenmark Pharmaceuticals regarding its alleged "false claims" on the utilisation of anti-viral FabiFlu (favipiravir) on COVID-19 patients with comorbidities.
-
No Game Changers: Medical Experts On Remdesiver, Favipiravir For COVID Treatment
With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".
-
Glenmark Shares Surge Over 35% On Regulatory Approval For COVID-19 Drug
Favipiravir being manufactured by Glenmark will be marketed by the name of Fabiflu and will be available in strength of 200 milligrams.
-
Glenmark Launches COVID-19 Drug Favipiravir At Rs 103 Per Tablet
As Glenmark Pharmaceuticals launched antiviral drug Favipiravir for the treatment of mild to moderate COVID-19 cases, medical experts on Saturday cautioned against seeing it as a "magic bullet" to treat the deadly virus but said it will be helpful as it can be orally administered and reduce viral load.
-
Glenmark Gets Approval For Favipiravir As COVID-19 Treatment
Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014.
-
Ivermectin, HCQ Dropped From One Covid Treatment List, Kept On Another
The Union health ministry has issued revised guidelines for management of Covid-infected patients, dropping many sought-after drugs like ivermectin, hydroxychloroquine and anti-viral Favipiravir from Covid treatment.
-
19 States Mapped With Remdesivir Manufacturers For Faster Supply
The centre has mapped manufacturers of the anti-viral drug remdesivir with 19 states that have high Covid case burden. This will ensure smooth and fast delivery of the medicine, the centre said in a statement.
-
Lupin Launches COVID-19 Drug Favipiravir In India At Rs 49 Per Tablet
Drug major Lupin on Wednesday announced the launch of its Favipiravir drug under the brand name "Covihalt" for the treatment patients with mild to moderate COVID-19 symptoms at Rs 49 per tablet in India.
-
Lupin Launches Its Version Of Favipiravir Drug To Treat COVID-19
Lupin's Covihalt will be available as 200 mg tablets in the form of a strip of 10 tablets, and priced at Rs 49 per tablet
-
Zenara Pharma Receives Nod To Sell Covid-19 Drug Favipiravir
Zenara Pharma: The Hyderabad-based company has received an approval to sell Favipiravir tablets for treating patients with mild to moderate symptoms of Covid-19.
-
Sun Pharma Company Launches COVID-19 Drug Favipiravir In India
Sun Pharmaceutical Industries has said it has launched Favipiravir (200 mg) in India under the brand FluGuard at an economical price of Rs 35 per tablet for the treatment of mild to moderate cases of COVID-19.
-
Hetero Labs Wins Approval To Sell COVID-19 Drug Favipiravir
The drug, priced at Rs 59 per tablet, is approved to treat mild to moderate COVID-19
-
Cipla Gets Regulatory Nod To Sell COVID-19 Drug
Cipla said it would launch favipiravir as "Ciplenza" in the first week of August, priced at Rs 68 (91 cents) per 200 mg tablet.
-
Cipla Set To Launch Favipiravir Drug For Treatment Of COVID Patients
Pharmaceutical firm Cipla is all set to launch Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process, for the treatment of COVID-19 patients, according to an official statement on Thursday.
-
Glenmark Defends Price Of Its COVID-19 Drug Favipiravir Version
Glenmark denied making any claims that "favipiravir alone" is effective in treatment of mild-to-moderate COVID-19 patients.
-
Central Drug Agency Seeks Clarification From Glenmark On Its COVID-19 Drug
The Drugs Controller General of India (DCGI) has asked for a clarification from Glenmark Pharmaceuticals regarding its alleged "false claims" on the utilisation of anti-viral FabiFlu (favipiravir) on COVID-19 patients with comorbidities.
-
No Game Changers: Medical Experts On Remdesiver, Favipiravir For COVID Treatment
With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".
-
Glenmark Shares Surge Over 35% On Regulatory Approval For COVID-19 Drug
Favipiravir being manufactured by Glenmark will be marketed by the name of Fabiflu and will be available in strength of 200 milligrams.
-
Glenmark Launches COVID-19 Drug Favipiravir At Rs 103 Per Tablet
As Glenmark Pharmaceuticals launched antiviral drug Favipiravir for the treatment of mild to moderate COVID-19 cases, medical experts on Saturday cautioned against seeing it as a "magic bullet" to treat the deadly virus but said it will be helpful as it can be orally administered and reduce viral load.
-
Glenmark Gets Approval For Favipiravir As COVID-19 Treatment
Favipiravir is made under the brand name Avigan by Japan's Fujifilm Holdings Corp and was approved for use as an anti-flu drug there in 2014.
